Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 16/20 | 0.47 |
| ▸ | CDC7 | O00311 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10197254 | 0.83 | CDC7 (0.45) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL19190841 | 0.74 | CYP19A1 (0.49) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL30768345 | 0.74 | CYP19A1 (0.49) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL28042900 | 0.74 | CYP19A1 (0.53) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL1892608 | 0.74 | CYP19A1 (0.49) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL18821827 | 0.74 | CYP19A1 (0.49) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL29509135 | 0.74 | MAPT (0.68) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL255050 | 0.74 | MAPT (0.68) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL3224575 | 0.74 | CDC7 (0.50) | CYP19A1MAPTCDC7CDK2 | |
| SCHEMBL6741126 | 0.71 | CYP19A1 (0.74) | CYP19A1MAPTCDC7CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119635-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2012-02-21 | — | — | US | disclosed |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2010-01-21 | — | — | US | disclosed |
| US-7598236-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | ABBOTT LABORATORIES (US) | 2008-04-24 | — | — | US | disclosed |
| US-7319106-B2 | Diazabicyclic central nervous system active agents | ABBOTT LABORATORIES (US) | 2008-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080097094-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | CYP19A1 1130/4885MAPT 1101/4885CDC7 929/4885 |
| US-20100016277-A1 | DIAZABICYCLIC CENTRAL NERVOUS SYSTEM ACTIVE AGENTS | GAP43, GABRE, CHRNA6 | CYP19A1 1130/4885MAPT 1101/4885CDC7 929/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.